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BACKGROUND: The global lapatinib expanded access programme provided access to lapatinib combined with capecitabine for women
with HER2-positive metastatic breast cancer (MBC) who previously received anthracycline, taxane and trastuzumab.
METHODS: Progression-free survival (PFS) and safety data for 356 patients recruited from the United Kingdom are reported. Efficacy
was assessed in 162 patients from the five lead centres, including objective tumour response rate (ORR), time to disease progression
(TTP) and efficacy in those with central nervous system (CNS) metastases. Correlation of PFS and ORR with previous capecitabine
treatment was also documented.
RESULTS: Overall, PFS for the 356 UK patients was 21 weeks (95% CI: 17.6–24.7). In the 162 assessable patients, ORR was 21% (95%
CI: 15–27%) and median TTP was 22 weeks (95% CI: 17–27). Efficacy was greater in capecitabine-naive patients (ORR 23 vs 16.3%,
P¼0.008). For 34 patients with CNS metastases, ORR was 21% (95% CI: 9–39%), with evidence of improvement in neurological
symptoms, and median TTP was 22 weeks (95% CI: 15–28).
CONCLUSIONS: Lapatinib combined with capecitabine is an active treatment option for women with refractory HER2-positive MBC,
including those with progressive CNS disease.
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Despite advances in treatment, breast cancer remains one of the
leading causes of cancer-related deaths in women. Approximately
25–30% of patients with breast cancer belong to a subgroup who
overexpress the ErbB2 (HER2) oncogene, and this is associated
with a higher risk of disease progression and death (Meric et al,
2002). Previous studies indicated increased resistance to hormonal
and cytotoxic therapies, and a poorer prognosis for patients with
tumours overexpressing HER2 (Nicholson et al, 2001; Slamon et al,
2001). The advent of trastuzumab has radically altered the outlook,
such that patients are surviving longer, with the pattern of relapse
and systemic disease changing. However, up to a third of patients
with HER2-positive metastatic breast cancer (MBC) are now
developing central nervous system (CNS) disease, either as a first
site of relapse or in addition, despite other sites of systemic disease
being well controlled and responding to trastuzumab-based
therapy (Bendell et al, 2003; Clayton et al, 2004). Until recently,
once patients developed trastuzumab resistance, further treatment
options were limited.
Lapatinib is an orally active small molecule, reversible tyrosine
kinase inhibitor (TKI) targeting both HER2 and ErbB1 (EGFR)
pathways, and has the potential to be used when trastuzumab
resistance develops. In an open-label randomised phase III trial
(EGF100151), lapatinib (1250mg daily) in combination with
capecitabine (2000mgm
–2 per day days 1–14 every 21 days)
significantly improved time to disease progression (TTP) com-
pared with capecitabine alone (2500mgm
–2 per day days
1–14, every 21 days). Patients enrolled into EGF100151 had
refractory locally advanced or MBC that had progressed after
previous treatment including trastuzumab. Interim analysis
showed statistically significant superiority of the combination
arm in terms of disease progression events (hazard ratio 0.51, 95%
CI: 0.35–0.74; Po0.001), and the study was stopped early by the
independent data and safety monitoring committee (Geyer et al,
2006), After completion analysis, the median TTP was 6.2 months
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sfor the combination arm compared with 4.3 months with
capecitabine alone, with a trend towards improved overall survival.
(HR 0.78, 95% CI: 0.55–1.12, P¼0.177). Interestingly, although
the number of patients developing CNS disease was small, fewer
patients developed brain metastases as first site of progression on
the combination compared with those on capecitabine alone (4 vs
13, P¼0.045) (Cameron et al, 2008).
These latter data suggested that lapatinib may help reduce the
risk of developing CNS metastases, and that it could be more
effective than the monoclonal antibody trastuzumab in treating
CNS disease once it occurs. A phase II study with single agent
lapatinib 750mg bid was undertaken in patients with HER2-
positive CNS metastases who had shown progression in their brain
after earlier whole-brain radiotherapy (WBRT), and clinical and
radiological responses were observed (Lin et al, 2008). Subse-
quently, a larger multicentre phase 2 study involving 242 patients
recently reported a 6% CNS objective response rate to lapatinib
alone (defined as X50% volumetric reduction of CNS lesion(s)
(Lin et al, 2009). In addition, a further 21% patients experienced a
X20% volumetric reduction in their CNS lesions, of whom many
had significant improvement in neurological symptoms. More
recently, Boccardo et al (2008) described a significant benefit in
their review of patients with CNS metastases from HER2-positive
breast cancer treated with capecitabine and lapatinib.
The global lapatinib expanded access programme (LEAP) study
was a single-arm open-label clinical trial that allowed access to
lapatinib in combination with capecitabine for patients with HER2
overexpressing breast cancers, who had previously received
anthracycline, taxane and trastuzumab, with the aim of providing
clinical benefit while awaiting regulatory approval in individual
countries, and further validating safety data observed in
EGF100151 in a larger population (Ryan et al, 2008). Entry criteria
were similar to those in the pivotal trial; in contrast, however,
earlier capectabine use was permitted and patients with cerebral
metastatic disease could participate, provided they were on a
steroid dose of p2mg per day of dexamethasone (or equivalent)
and had a performance status (PS) of 0 to 2.
We have reviewed our experience of using capecitabine in
combination with LEAP looking at both efficacy (progression-free
survival, PFS) and safety across the entire United Kingdom. In a
cohort from the five largest participating sites (Royal Marsden
Hospital, Mount Vernon/Hillingdon, Nottingham, Essex and
The Christie Hospital), we looked in more detail at efficacy,
systemically and in the CNS. Tumour response rate, TTP and
treatment-related toxicities were assessed and compared with
those reported in EGF100151. In addition, we performed a
separate analysis of the cohort of patients with CNS metastases
to assess response in this group.
MATERIALS AND METHODS
Study design
This was a single-arm open-label expanded access study of
lapatinib in combination with capecitabine for male and female
patients with HER2 overexpressing locally advanced breast cancer
(LABC) defined as stage IIIb/c with a T4 lesion or metastatic (stage
IV) disease. The primary objective was to provide clinical benefit
to patients who were not eligible for other ongoing lapatinib
clinical trials, with the secondary objective being to evaluate
serious adverse events (SAEs) associated with this combination
therapy in this population of Her2-overexpressing metastatic and
LABC. In total, 4283 patients were recruited worldwide with 356
(8.3%) coming from the United Kingdom; across the five sites in
this report, 162 patients were recruited, of whom 34 had evidence
of CNS disease. Entry criteria differed from those of EGF100151, in
that patients were eligible for LEAP regardless of any previous
capecitabine use, presence of CNS involvement or absence of
measurable disease. Major inclusion criteria were as follows: adults
418 years with disease progression as defined by Response
Evaluation Criteria in Solid Tumors (RECIST) after previous
treatment with anthracyclines, taxanes and trastuzumab for HER2
overexpressing LABC or MBC; ECOG PS 0 to 2; life expectancy 48
weeks; adequate haematological, renal and hepatic function; and
adequate cardiac function as defined by multigated acquisition
scan (MUGA) or echocardiogram (ECHO). Patients with CNS
disease were allowed to participate in the study, provided they
were asymptomatic and on p2mg dexamethasone (or equivalent)
per day. Exclusion criteria included symptomatic angina,
congestive cardiac failure, arrythmias, malabsorption or other
gastrointestinal disease affecting absorption of oral medications,
pregnancy or lactation and uncontrolled infection. The study was
sponsored by GlaxoSmithKline, and received approval from MREC
and local hospital R&D departments.
Treatments
Doses were capecitabine 2000mgm
–2per day in two divided doses
for 14 days, followed by a 7-day rest and lapatinib 1250mg once
daily continuously. Treatment continued until disease progression,
unacceptable toxicity or patient withdrawal from the study. Dose
reductions of up to 50% of the planned lapatinib dose, and dose
reductions or delay of the planned capecitabine dose, were
permitted according to the severity and recurrence of toxicity
experienced.
Assessments
Patients were assessed for response every 6 weeks for the first 6
months of study, then every 12 weeks, or at a frequency after the
study site institution’s standard. Data were collected from patient
case notes, electronic patient records and case report forms across
the five participating sites. Duration of treatment, number of cycles
given, previous treatment with capecitabine, sites of metastatic
disease, number of lines of previous therapy and main site of
disease progression at entry were all documented. Best response
to treatment as assessed by the investigator was recorded, and
patients were deemed to have had a response if they had a
complete response (CR) or partial response (PR) and ‘clinical
benefit’ if there had been CR/PR or stable disease (SD) for 46
months. Response was assessed by RECIST criteria as per study
protocol. TTP was defined as the time from initiation of study
medication until the earliest date of disease progression as
assessed by the investigator. Patients with CNS disease were
included in the main analysis and also assessed independently.
Safety
Patients were assessed for safety at each site with clinical and
laboratory evaluations every 3 weeks and cardiac monitoring,
either MUGA or ECHO, every 12 weeks as per protocol. At the time
of data cutoff, 4283 subjects were enrolled in the programme,
including 356 subjects from the United Kingdom whose data will
be reviewed below. The global safety data have been reported
separately (Capri et al, 2009) and we have provided a summary of
key safety data for the UK patients.
Statistics
Response was compared between groups by means of Kendalls
tau-b. TTP was illustrated by Kaplan–Meier curves and patients
were analysed separately according to previous capecitabine
exposure. Differences between groups in objective tumour
response rate (ORR) with and without previous capecitabine were
assessed by means of the log-rank statistic.
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Patients and treatment
Between February 2007 and June 2008, 356 UK patients were
recruited across 27 sites, accounting for 8.3% of the global LEAP
population. For our efficacy analysis, 162 patients were enrolled
across five major UK sites (Table 1). All patients had been
previously treated with anthracyclines, taxanes and trastuzumab,
as per protocol; 62 of the 162 (38%) patients had received
capecitabine for MBC previously. Patients had received 0–5þ
lines of previous treatment in the advanced setting (median of 2.7
lines), with 71 (43.8%) patients having received X3 previous lines
of treatment. The median age of our cohort was 51 years (range
28–75), and all were women. The median duration of treatment
was 4 months (range 0–24), with a median number of six cycles of
treatment completed (range 1–27).
Clinical efficacy
Across the whole UK study population (n¼356), median PFS was
21 weeks (95% CI: 17.6–24.7) and median OS was 40.4 weeks (95%
CI: 34.7–44.1). In the efficacy cohort (n¼162), median PFS was
22 weeks (95% CI: 17–27), which was comparable with both
the overall UK and global study data (PFS 21.1 weeks, 95% CI:
20.1–22.3). Best tumour response was recorded as assessed by the
investigator, according to standard RECIST criteria in those with
measurable disease, and clinically in those with skin or chest wall-
only disease. In all, 157 of the 162 patients had a formal response
assessment, with 21% (95% CI: 15–27%) of patients documented
as having an objective tumour response (CR/PR), and 50% (95%
CI: 42–58%) deemed to have had clinical benefit that included
SD X6 months (Table 2). The five other patients progressed or
died before the first 6-week response assessment. There was a
significant difference in both ORR and clinical benefit rate (CBR)
between those who had received capecitabine previously and those
who had not (Table 2), with greater efficacy being observed
in patients who were capecitabine naive (ORR 23 vs 16.3%,
P¼0.008).
TTP was recorded in weeks and illustrated by means of
a Kaplan–Meier curve (Figure 1). Median TTP was 22 weeks
(95% CI: 17–27) and differed according to previous capecitabine
exposure, with patients who had received prior capecitabine
having a poorer TTP than those patients who had not; median TTP
was 15 weeks (95% CI: 10–21) compared with 26 weeks (95% CI:
20–32) P¼0.02 (Figure 2).
Patients with CNS disease
Of the cohort of 162 patients, 34 had documented CNS
involvement. The median age among this subgroup of patients
was younger (49 years, range 28–64 years) compared with that of
the overall LEAP study population, which had a median age of 51
years (range 28–75 years) Patients had a similar number of lines of
previous treatment (mean 2.4, range 1–5þ) compared with the
overall study population (mean 2.5) (Table 3). In 23 of the 34
Table 1 Patient characteristics and previous treatments given for the
cohort of 162 patients from the five centres studied
Patients 162
Centre RMH 47
Mount Vernon 27
Nottingham 38
Essex 21
Christie Hospital 29
Age Median (range) 51 (28–75)
Main site of disease Local/soft tissue only 33
Bone 9
Visceral (liver/lung/mediastinum) 97
Brain
a 23
Prior chemotherapy Anthracycline/taxane/trastuzumab 162 (100%)
Previous capecitabine
Yes 62 (38.3%)
No 99
N/A 1
Number of previous 0 5
lines of treatment 1 29
25 6
34 4
41 3
5+ 14
Not recorded 1
aThere were 34 patients in total with central nervous system disease, but only 23 had
progression in the brain or the brain as the main site of metastatic disease at entry
into the trial.
Table 2 Duration of and response to treatment overall and according to
prior capecitabine exposure for the 162 patients assessed for response
Best tumour response CR 2 (1.2%)
PR 31 (19.7%)
SD 90 (57.3%)
PD 31 (19.7%)
NA/not recorded 5
Objective response rate
(CR and PR)
33/157 21% (95% CI: 15–27%)
Clinical benefit rate (CR, PR and
SD46/12)
78/157 50% (95% CI: 42–58%)
Best tumour response according
to previous capecitabine exposure
Yes (n¼62) No (n¼99)
CR 1 (1.6%) 1 (1%)
PR 9 (14.5%) 22 (22%)
SD 28 (45.1%) 61 (61.6%)
PD 21 (33.9%) 13 (13%)
N/A 3 2
Abbreviations: CR¼complete response; PD¼progressive disease; PR¼partial
response; SD¼stable disease.
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Figure 1 Time to progression illustrated by a Kaplan–Meier Curve for
the 162 patients assessed for response.
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spatients, the brain was the predominant site of disease at entry to
the study; however, only 17 out of 34 (50%) had overt progression
in the brain and/or neurological symptoms at entry, other patients
having more significant systemic progression with largely stable
brain disease. Most patients (94%) had received WBRT between 1
and 412m before entry into LEAP, one patient had previously
undergone neurosurgery alone, and two patients received no
previous CNS loco-regional treatment. The median duration of
treatment was 5 months (range 1–15) and a median number of
seven cycles of treatment were completed (range 2–22).
Best tumour response in CNS metastases was assessed and
recorded by the investigator, according to RECIST, and 33 (97%)
patients had a formal response assessment by CT or MRI imaging.
In total, 7 out of 33 (21%; 95% CI: 9–39%) patients were
documented as having an objective response (one CR, six PRs),
and 16 out of 33 (48%; 95% CI: 31–60%) were deemed to have had
clinical benefit (Table 3). One patient died before the first 6-week
response assessment occurred. The ORR in CNS was lower in those
previously treated with capecitabine, with 2 out of 12 patients
(16.7%) responding compared with 6 out of 20 patients (30%) in
the capecitabine-naive group (P¼0.2); one patient had unknown
previous capecitabine exposure. Two illustrative case histories
showing the effects of lapatinib and capecitabine in CNS
metastases are described in Figures 3 and 4.
For the 34 patients with CNS metastases, most of whom had
progressed despite previous radiotherapy, the median TTP was
22 weeks (95% CI: 15–28). The numbers were too small to be
statistically significant, but again response varied with capecita-
bine exposure. Median TTP for those previously treated with
capecitabine was 17 weeks (95% CI: 13–22) compared with 30
weeks (95% CI: 15–45) for the capecitabine-naive group (P¼0.06)
(Figure 5).
Safety data
In the UK patients (n¼356), as of 30 September 2008, a total of
163 SAEs were reported from 89 (25%) subjects. The most
frequently reported SAE was diarrhoea with 18 reports, 94% of
which were assessed as treatment related. Overall, 42% (69 out
of 163) of the SAEs reported were assessed as drug related by the
investigator. Diarrhoea, vomiting, nausea, dehydration and
palmar-plantar erythrodysaesthesia syndrome are included in the
core safety information for lapatinib. A summary of the most
frequently reported SAEs can be found in Table 4.
Left ventricular ejection fraction (LVEF) was evaluated using
MUGA scans or echocardiogram during lapatinib phase I, II and
III trials. In the UK study population, there was no significant
change in LVEF during treatment (Figure 6). Two subjects in the
United Kingdom experienced a decreased ejection fraction as
defined by the protocol-specific serious definition (a drop of
420% from baseline and below the institution’s lower limit of
normal). They experienced a drop in LVEF of 35% and 38.5% from
baseline at 120 and 48 days, respectively, after starting treatment.
In both cases, the decrease was considered to be possibly related to
treatment with laptinib and capecitabine.
No pulmonary events in the United Kingdom met the study
criteria for SAE reporting and withdrawal (pulmonary symptoms
that are NCI CTC Grade 3 or greater). Ten serious haepatobiliary
events (defined as ALT48xULN, ALT45 ULN for 42/52,
ALT43 ULN with clinical signs or symptoms of hepatitis or
ALT43 ULN Bilirubin42 ULN with 435% direct) were
reported in the United Kingdom: one event was considered to be
possibly associated with lapatinib and capecitabine administration,
three serious haepatobiliary events were associated with disease
progression and were not thought to be related to lapatinib and
capecitabine administration, and five of the remaining six events
were associated with disease progression and seriousness may have
been due to an event other than the haepatobiliary event.
DISCUSSION
The overall efficacy and safety of the UK LEAP cohort of 356
patients matches the findings of the recently published Global
LEAP study of 4283 patients (Capri et al, 2009). Within our more
detailed group of 162 UK patients, we documented an ORR to
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Figure 2 Time to progression by previous capecitabine exposure,
illustrated by Kaplan–Meier Curves for the cohort of patients assessed for
response.
Table 3 Treatment centres, patient characteristics and best response to
treatment for the subgroup of patients with brain metastases from the 162
patients assessed for response
Patients with brain mets
Patients 34
Centre RMH 14
Mount Vernon 4
Nottingham 4
Essex 3
Christie 9
Age Median (range) 49 (28–64)
Number of lines chemotherapy 1 5
treatment for MBC pre-trial 2 15
31 1
41
5+ 1
Mean number 2.4
Best response CR 1 (3%)
PR 6 (18.2%)
SD 19 (57.6%)
PD 6 (18.2%)
N/A or not
recorded
1
Objective response rate (CR/PR) 7/33 21% (95% CI: 9–39%)
Clinical benefit rate
(CR/PR/SD46 months)
16/33 48% (95% CI: 31–60%)
Abbreviations: CR¼complete response; MBC¼metastatic breast cancer; PD¼pro-
gressive disease; PR¼partial response; SD¼stable disease.
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slapatinib and capecitabine of 21%, and a clinical benefit of 50% in
a heavily pre-treated population of women with HER2-positive
advanced breast cancer. This compares very favourably with the
pivotal EGF100151 study, in which earlier treatment with
capecitabine was not permitted, and ORRs of 22% were reported
for lapatinib and capecitabine compared with 14% in the
capecitabine alone group, with a CBR of 27% and 18%, respectively
(Geyer et al, 2006).
The cohort of UK patients assessed for response in this report
showed a median TTP of 22 weeks, although it should be noted
that these patients differed from the EGF100151 population in that
they were more heavily pre-treated. In particular the UK cohort
included patients with CNS metastases and 38.3% had received
capecitabine previously. We showed a significant difference in TTP
in our patients between those who had received prior capecitabine
and those who had not (15 vs 26 weeks, P¼0.02), with a similar
benefit and trend towards significance in the subset with CNS
disease (17 vs 30 weeks, P¼0.06). This is again comparable with
the global data from the LEAP/ATU analysis in which PFS was 18.4
weeks (95% CI: 17.9–19.4) for those receiving capecitabine earlier
compared with 23.9 weeks (95% CI: 22.3–25) for those who were
capecitabine naive. Indeed, the TTP of 26 weeks that we report for
Pre-treatment Response after two cycles
Figure 3 Response of CNS metastases to lapatinib and capecitabine in the absence of previous whole-brain radiotherapy. This 61-year-old woman with
HER2-positive breast cancer was diagnosed in 2002. Subsequently, she received three lines of trastuzumab-containing chemotherapy for metastatic breast
cancer (paclitaxel, vinorelbine and capecitabine). In July 2007, she developed headache, nausea and vomiting. CT brain revealed three metastases with
associated cerebral oedema. She required only a very small dose of steroid and was entered into the LEAP study without previous local therapy (neither
neurosurgery nor WBRT) and a combination of capecitabine and lapatinib was her first treatment for CNS disease. She had an excellent clinical response
after two cycles, with complete resolution of her headache, nausea and intermittent vomiting, as well as radiological improvement on repeat CT scan with
resolution of cerebral oedema and volume reduction of metastases.
Pre-treatment After two cycles
Figure 4 Case study 2 and scan pictures illustrating response. This 47-year-old woman was diagnosed in 1995 with HER2-positive primary breast cancer.
In June 2005, she developed metastatic disease (bones, liver and lung) and was treated with eight cycles of docetaxel, trastuzumab and pamidronate to which
she had a good response, continuing on maintenance trastuzumab and pamidronate with stable disease. In August 2006, she developed headache and left
hand tremor, and a CT scan of her brain confirmed multiple cerebral metastases that were treated with whole-brain radiotherapy, whereas her systemic
disease remained stable on continued trastuzumab and pamidronate. In February 2007, she developed increasing headache, and a CT scan confirmed CNS
disease progression. In March 2007, she commenced capecitabine and lapatinib in the LEAP study, and, within 6 weeks, a repeat CT scan showed a significant
reduction in tumour volume. Her CNS disease remained stable for a further 14 cycles of treatment before progressing in March 2008.
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investigator-assessed median TTP of 23.6 weeks (5.9 months)
reported in EGF100151 (Geyer et al, 2006).
Safety in the overall UK population was again comparable with
that of EGF100151, with no significant differences in LVEF being
documented over the study period in either case. Two patients
(n¼356) in the UK LEAP study developed a decrease in LVEF and
five patients were reported as having an ‘asymptomatic cardiac
event’ in EGF100151, four of whom were in the combination
therapy group.
It is well documented that patients with HER2 overexpressing
tumours seem to have a higher incidence of intracranial metastases
(up to 30%) (Clayton et al, 2004), and the brain is often described
as a ‘sanctuary site’ because of difficulties with cytotoxic agents or
monoclonal antibodies such as trastuzumab crossing the ‘blood–
brain barrier’. There are anecdotal reports of responses to
capecitabine monotherapy in CNS metastases in breast cancer
(Ekenel et al, 2007). More recently, there have been further reports
of responses to lapatinib-based therapy. After an initial single-
centre phase II study of lapatinib monotherapy in patients with
HER2-positive breast cancer who developed progressive CNS
metastases after prior loco-regional therapy (Lin et al, 2008), a
larger multicentre phase II study involving 242 patients reported a
6% CNS ORR to lapatinib alone (Lin et al, 2009). In an exploratory
analysis, a further 21% patients experienced a X20% volumetric
reduction in CNS lesions, with many having significant improve-
ment in neurological symptoms. An association was observed
between volumetric reduction and improvement in PFS and
neurological signs and symptoms. Subsequently, within this study,
a cohort of 50 patients whose CNS disease progressed on lapatinib
monotherapy entered an extension phase involving treatment with
both capecitabine and lapatinib, with an ORR of 20%, with 40%
patients having a volumetric reduction of X20% in their CNS
lesions.
In a previous report of 138 patients with brain metastases
treated with lapatinib and capecitibine within the LEAP study and
the French ATU programme, Boccardo et al (2008) reported an
ORR of 18% (CR and PR), with a further 47% of patients achieving
SD, although the duration of SD was not recorded. They too noted
an improvement in neurological symptoms in 25% of patients.
Their patient population had a previous exposure to capecitabine
that was similar to ours, with 42% having received it before the
study. Thus, our subgroup of 34 patients with CNS metastases who
had progressed after previous WBRT compares favourably with
these previous studies, with an investigator-assessed response rate
of 21% and evidence of clinical benefit in half of the treated
patients. As the two case histories illustrate (Figures 3 and 4), the
oral regimen of lapatinib and capecitabine can improve neurolo-
gical symptoms and cause CNS tumours to shrink, with disease
control in some patients achieved for up to a year. For patients
with symptomatic CNS disease progressing after earlier WBRT,
prognosis is normally very poor (weeks to a few months at most);
hence, this level of benefit in a hitherto ‘difficult-to-treat’ scenario
represents meaningful clinical efficacy.
In EGF100151, although the numbers were small, fewer patients
in the combination arm developed CNS metastases compared with
those on capecitabine monotherapy (4 vs 13), suggesting that
lapatinib may also have an effect in prevention. Lapatinib, being a
small molecule TKI, seems to penetrate more readily into the CNS,
as illustrated by pre-clinical data that showed in vitro inhibition of
phosphorylation of EGFR, HER2, downstream signalling proteins
and cell proliferation in brain-seeking breast cancer cell lines
MDA-MB-231-BR (with and without HER2), and a corresponding
50–53% reduction in the number of brain metastases developed by
nude mice injected with these cells when treated with lapatinib,
compared with a control group (Gril et al, 2008). It will be
interesting to observe whether outcomes from the adjuvant
ALTTO trial differ between arms of the study in the numbers of
patients developing CNS metastases at relapse. If lapatinib proves
to be not only an effective treatment for HER2-positive breast
cancer but also helps reduce the likelihood of developing CNS
metastases when given in an adjuvant setting, it will have a
significant impact on the course of this disease.
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Figure 5 Time to progression for the subgroup of patients with brain
metastases (n¼34), according to previous capecitabine exposure,
illustrated by Kaplan–Meier Curves, from the cohort of 162 patients
assessed for response.
Table 4 Most frequently reported drug-related SAEs in the United
Kingdom
MedDRA PT
Drug-related
SAEs % (n¼356)
Diarrhoea 17 4.8
Vomiting 11 3
Nausea 6 1.7
Dehydration 4 1.3
Chest pain 3 0.8
Pyrexia 3 0.8
Neutropenia 3 0.8
Dyspnoea 2 0.56
Pulmonary embolism 2 0.56
Fatigue 2 0.56
Cellulitis 2 0.56
Mucosal inflammation 1 0.28
Palmar–plantar erythrodysaesthesia syndrome 1 0.28
Abbreviations: SAEs¼serious adverse events. Italicized events are listed in the core
safety information for lapatinib.
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Figure 6 Changes in LVEF from the overall UK Safety data (n¼356)
(graph shows the mean LVEF and 95% CI at each time point.).
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supporting the use of lapatinib in combination with capecitabine
in Her2þ MBC, particularly in patients who are capecitabine
naive and in those who have progressive and symptomatic
CNS metastases following earlier WBRT. There is now increasing
evidence to suggest that this is an effective and reasonably
well-tolerated treatment for patients who progress in CNS as well
as in non-CNS sites after previous treatment with trastuzumab-
containing regimens. Given the overall improved outlook
and better survival for patients with HER2-positive breast cancer,
there is a real need for further targeted therapies once patients
have become trastuzumab resistant, and in particular, for those
with CNS disease for whom treatment options are even more
limited.
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